PortfoliosLab logoPortfoliosLab logo
SPRO vs. TLSA
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

SPRO vs. TLSA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Spero Therapeutics, Inc. (SPRO) and Tiziana Life Sciences PLC (TLSA). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

SPRO vs. TLSA - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
SPRO
Spero Therapeutics, Inc.
0.43%126.21%-29.93%-15.03%-89.19%-17.43%101.66%56.34%-20.85%
TLSA
Tiziana Life Sciences PLC
-21.48%114.02%24.32%-6.43%-37.66%-52.48%86.96%-27.52%-10.78%

Fundamentals

EPS

SPRO:

-$0.78

TLSA:

-$0.53

Total Revenue (TTM)

SPRO:

$35.77M

TLSA:

$0.00

Gross Profit (TTM)

SPRO:

-$72.47M

TLSA:

-$316.00K

EBITDA (TTM)

SPRO:

-$45.15M

TLSA:

-$38.66M

Returns By Period

In the year-to-date period, SPRO achieves a 0.43% return, which is significantly higher than TLSA's -21.48% return.


SPRO

1D
4.46%
1M
7.83%
YTD
0.43%
6M
24.47%
1Y
225.00%
3Y*
17.30%
5Y*
-30.35%
10Y*

TLSA

1D
-5.65%
1M
-19.31%
YTD
-21.48%
6M
-45.83%
1Y
8.33%
3Y*
2.34%
5Y*
-15.71%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SPRO vs. TLSA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRO
SPRO Risk / Return Rank: 9090
Overall Rank
SPRO Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
SPRO Sortino Ratio Rank: 9999
Sortino Ratio Rank
SPRO Omega Ratio Rank: 9898
Omega Ratio Rank
SPRO Calmar Ratio Rank: 9494
Calmar Ratio Rank
SPRO Martin Ratio Rank: 8787
Martin Ratio Rank

TLSA
TLSA Risk / Return Rank: 4646
Overall Rank
TLSA Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
TLSA Sortino Ratio Rank: 5252
Sortino Ratio Rank
TLSA Omega Ratio Rank: 4848
Omega Ratio Rank
TLSA Calmar Ratio Rank: 4343
Calmar Ratio Rank
TLSA Martin Ratio Rank: 4343
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRO vs. TLSA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Spero Therapeutics, Inc. (SPRO) and Tiziana Life Sciences PLC (TLSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SPROTLSADifference

Sharpe ratio

Return per unit of total volatility

0.90

0.09

+0.81

Sortino ratio

Return per unit of downside risk

6.29

0.87

+5.42

Omega ratio

Gain probability vs. loss probability

1.78

1.09

+0.69

Calmar ratio

Return relative to maximum drawdown

5.16

0.08

+5.07

Martin ratio

Return relative to average drawdown

9.02

0.16

+8.86

SPRO vs. TLSA - Sharpe Ratio Comparison

The current SPRO Sharpe Ratio is 0.90, which is higher than the TLSA Sharpe Ratio of 0.09. The chart below compares the historical Sharpe Ratios of SPRO and TLSA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


SPROTLSADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.90

0.09

+0.81

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.20

-0.17

-0.03

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.14

-0.04

-0.10

Correlation

The correlation between SPRO and TLSA is 0.07, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

SPRO vs. TLSA - Dividend Comparison

Neither SPRO nor TLSA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SPRO vs. TLSA - Drawdown Comparison

The maximum SPRO drawdown since its inception was -97.46%, roughly equal to the maximum TLSA drawdown of -94.03%. Use the drawdown chart below to compare losses from any high point for SPRO and TLSA.


Loading graphics...

Drawdown Indicators


SPROTLSADifference

Max Drawdown

Largest peak-to-trough decline

-97.46%

-94.03%

-3.43%

Max Drawdown (1Y)

Largest decline over 1 year

-39.80%

-53.20%

+13.40%

Max Drawdown (5Y)

Largest decline over 5 years

-97.13%

-86.76%

-10.37%

Current Drawdown

Current decline from peak

-89.40%

-83.26%

-6.14%

Average Drawdown

Average peak-to-trough decline

-61.75%

-70.04%

+8.29%

Ulcer Index

Depth and duration of drawdowns from previous peaks

22.77%

28.80%

-6.03%

Volatility

SPRO vs. TLSA - Volatility Comparison

The current volatility for Spero Therapeutics, Inc. (SPRO) is 13.13%, while Tiziana Life Sciences PLC (TLSA) has a volatility of 20.16%. This indicates that SPRO experiences smaller price fluctuations and is considered to be less risky than TLSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


SPROTLSADifference

Volatility (1M)

Calculated over the trailing 1-month period

13.13%

20.16%

-7.03%

Volatility (6M)

Calculated over the trailing 6-month period

32.66%

51.29%

-18.63%

Volatility (1Y)

Calculated over the trailing 1-year period

252.14%

89.30%

+162.84%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

151.63%

92.73%

+58.90%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

125.84%

113.28%

+12.56%

Financials

SPRO vs. TLSA - Financials Comparison

This section allows you to compare key financial metrics between Spero Therapeutics, Inc. and Tiziana Life Sciences PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJuly
3.05M
0
(SPRO) Total Revenue
(TLSA) Total Revenue
Values in USD except per share items